tiprankstipranks
Trending News
More News >

4D Molecular Therapeutics Holds Annual Stockholders Meeting

Story Highlights
  • 4D Molecular Therapeutics held its 2025 Annual Meeting virtually on June 17.
  • Stockholders elected directors, ratified auditors, and approved executive compensation policies.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
4D Molecular Therapeutics Holds Annual Stockholders Meeting

Don’t Miss TipRanks’ Half-Year Sale

4D Molecular Therapeutics ( (FDMT) ) has issued an update.

On June 17, 2025, 4D Molecular Therapeutics held its Annual Meeting of Stockholders virtually, where 38,470,536 shares were voted on four proposals. The stockholders elected Class II directors, ratified the selection of PricewaterhouseCoopers LLP as the independent auditor, approved executive compensation, and decided to hold annual advisory votes on executive compensation.

The most recent analyst rating on (FDMT) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.

Spark’s Take on FDMT Stock

According to Spark, TipRanks’ AI Analyst, FDMT is a Neutral.

4D Molecular Therapeutics faces considerable financial and valuation challenges, reflected in its negative P/E ratio and cash flow issues. While technical indicators show short-term bullish momentum, the stock is overbought, suggesting a potential correction. The company’s future hinges on successful research outcomes and maintaining external financing.

To see Spark’s full report on FDMT stock, click here.

More about 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of gene therapy products. The company is engaged in creating transformative therapies for patients with serious genetic diseases.

Average Trading Volume: 591,622

Technical Sentiment Signal: Sell

Current Market Cap: $189.5M

See more data about FDMT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1